Compare GLDD & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | EMBC |
|---|---|---|
| Founded | 1890 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.6M | 719.7M |
| IPO Year | 2006 | N/A |
| Metric | GLDD | EMBC |
|---|---|---|
| Price | $12.79 | $11.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 365.2K | ★ 621.3K |
| Earning Date | 11-04-2025 | 11-25-2025 |
| Dividend Yield | N/A | ★ 5.13% |
| EPS Growth | ★ 36.27 | 20.90 |
| EPS | 1.19 | ★ 1.62 |
| Revenue | $834,599,000.00 | ★ $1,080,400,000.00 |
| Revenue This Year | $12.43 | $2.18 |
| Revenue Next Year | $4.92 | $0.09 |
| P/E Ratio | $10.81 | ★ $7.22 |
| Revenue Growth | ★ 12.53 | N/A |
| 52 Week Low | $7.51 | $9.20 |
| 52 Week High | $13.10 | $21.23 |
| Indicator | GLDD | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 30.25 |
| Support Level | $12.63 | $12.10 |
| Resistance Level | $13.10 | $12.56 |
| Average True Range (ATR) | 0.32 | 0.75 |
| MACD | 0.05 | -0.26 |
| Stochastic Oscillator | 81.60 | 4.84 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.